IndraLab

"Acute generalized exanthematous pustulosis caused by hydroxychloroquine in a patient with rheumatoid arthritis and CARD14 mutation: Case report."

"In this case, the patient had a 12-year history of RA, for which she had been treated with medications, including hydroxychloroquine."

"As several studies suggested an association between hydroxychloroquine and lipid concentrations, Munro et al conducted a randomized one-year trial in patients with established RA where 100 patients were either treated with hydroxychloroquine (n = 51) or gold (n =."

"Prevalence of COVID-19 in patients with rheumatoid arthritis (RA) already treated with hydroxychloroquine (HCQ) compared with HCQ-naive patients with RA : a multicentre cross-sectional study."

"They demonstrated that CD4 + T cells from RA patients treated with hydroxychloroquine (HCQ) showed increased levels of LC3-II and autophagosomes number compared with cells isolated from healthy donors."

"Chen et al.Table 1 Baseline demographic and clinical characteristics of patients with rheumatoid arthritis who received biological therapy.VariablesAdalimumab (n = 32) Abatacept (n = 38) Tocilizumab (n = 33) P-valueAge, years Gender, female (%) Body mass index, kg/m2 Baseline DAS28 score Baseline GS synovitis score Baseline PD score Smoking Alcohol consumption Diabetes Hypertension Liver disease Kidney disease Heart disease Pulmonary disease Use of other RA mediationsMethotrexate Hydroxychloroquine Leflunomide Cyclosporin Sulfasalazine55.37 AE 13.06 27 (84.4) 22.58 AE 3.86 6.59 AE 0.44 1.53 AE 0.51 0.97 AE 0.83 2 (6.3) 2 (9.4) 3 (9.4) 8 (25.0) 3 (9.4) 0 (0) 3 (9.4) 4 (12.5) 23 (71.9) 26 (81.3) 9 (28.1) 3 (9.4) 2 (6.3) 56.14 AE 16.60 14 (73.7) 22.41 AE 3.55 6.54 AE 0.67 1.48 AE 0.50 0.85 AE 0.82 4 (10.5) 4 (10.5) 6 (15.8) 6 (25.8) 0 (0) 2 (5.3) 6 (15.8) 2 (5.3) 24 (63.2) 30 (78.9) 8 (21.1) 0 (0) 2 (5.3) 54.63 AE 14.72 8 (72.7) 23.06 AE 4.32 6.34 AE 0.64 1.54 AE 0.51 1.0 AE 0.76 0 (0) 6 (18.2) 6 (18.2) 15 (45.5) 6 (18.2) 0 (0) 0 (0) 3 (9.1) 18 (54.5) 18 (54.5) 6 (18.2) 6 (18.2) 0 (0) 0.73 0.564 0.902 0.430 0.648 0.347 0.564 0.723 0.681 0.199 0.196 0.317 0.369 0.6980.547 0.274 0.314 0.196 0.703 RA, rheumatoid arthritis; GS, gray scale; PD, power Doppler; DAS28, Disease Activity Score in 28 joints.has evaluated changes in synovitis between treatment with adalimumab, tocilizumab and abatacept."

"Of the 68 RA patients treated with HCQ, 58/68 (85%) were dramatically responsive to this medication."

"[Early electroretinografic changes in elderly RA patients treated with hydroxychloroquine]."

"A 35-year-old male patient with a medical history of chronic hepatitis c virus (genotype 1a) since 1999 and rheumatoid arthritis (RA) treated with hydroxychloroquine was examined in the hepatology unit of our Hospital."

"The aim of the present study was to observe the kind and frequency of laboratory tests used in the screening for side e!ects of DMARDs in patients with RA in daily rheumatological practice in The Netherlands.Material and methodsStudy designA retrospective, multi-center cohort study of laboratory tests was performed in RA patients who were treated with AMALs (including hydroxychloroquine and chloroquine), AU, DPEN, SASP, MTX, or AZA."

"In Case 1, a 68-year-old Caucasian woman with a history of RA was initially treated with hydroxychloroquine."

"The adjusted incidence of COVID-19 hospitalisation was estimated for patients with RA; spondyloarthritis including psoriatic arthritis; connective tissue disease; vasculitides; and non IRD individuals.Further, the incidence of COVID-19 hospitalisation was estimated for patients with RA treated respectively non treated with TNF-inhibitors, hydroxychloroquine, or glucocorticoids.Lastly, the incidence of severe COVID-19 infection (intensive care, acute respiratory distress syndrome, or death) among hospital admitted patients was estimated for RA and non IRD individudals."

"5 Interestingly, quinacrine, chloroquine, and hydroxychloroquine (plaquenil) induce remission of systemic lupus erythematosus and rheumatoid arthritis."

"Other frequently used DMARDs include sulphasalazine, hydroxychloroquine and leflunomide.The cause of RA remains unknown, but the last 20 years have seen an accumulation of insights into its pathogenet[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

"Finally, these autoantibodies, together with RF and probably other surrogate genetic or biochemical markers, may facilitate primary prevention of RA by allowing high-risk persons to be treated with agents such as hydroxychloroquine prior to the onset of the disease.REFERENCES [1] Vossenaar ER, van Venrooij WJ."